Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients
Nuwellis (Nasdaq: NUWE) announced promising clinical data supporting the use of Aquadex FlexFlow® System for fluid management in high-risk postoperative coronary artery bypass grafting (CABG) patients. A study published in the Journal of Cardiac Surgery revealed a 100% 30-day survival rate among 17 patients treated with ultrafiltration, despite a high mean mortality score of 5.7%. This innovative approach addresses fluid overload, a significant risk factor for morbidity and mortality in CABG surgeries. The company aims to further research the application of Aquadex technology across more institutions.
- 100% 30-day survival rate in patients treated with ultrafiltration.
- Ultrafiltration addresses fluid overload in high-risk CABG patients.
- Aquadex therapy reflects company strategy successfully increasing total revenue in critical care by approximately 40%.
- Progress in other key areas, including heart failure and pediatrics.
- None.
Data show ultrafiltration for post-operative CABG patients provides a safe and effective method for managing fluid balance and reducing mortality rates
MINNEAPOLIS, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the publication of key clinical data supporting the use of ultrafiltration with the Aquadex FlexFlow® System in high-risk postoperative coronary artery bypass grafting (CABG) patients in the Journal of Cardiac Surgery.
The study, “The Use of Simple Ultrafiltration Technology as a Fluid Management Strategy for High-Risk Coronary Artery Bypass Grafting Surgery,” is a real-world retrospective review of postoperative isolated CABG patients who were treated in the Division of Cardiothoracic Surgery at Baylor Scott & White Health in Temple, Texas between January 1, 2020 and July 31, 2021. A total of 254 CABG procedures were performed during this period, and ultrafiltration was used in 17 (
“Ultrafiltration technology has been used for decades to successfully treat advanced heart failure patients and data hav been published to demonstrate its outcomes, but its application in cardiac surgery to treat fluid overload is innovative,” said Daniel Beckles, M.D., Surgical Director of Heart Transplantation and Mechanical Circulatory Support at Baylor Scott & White Health and the study’s lead author. “These favorable results are consistent with the clinical findings in other large academic centers using ultrafiltration technology in cardiac surgery, and we are eager to gather additional multi-institutional data about the use of Aquadex for this challenging patient population.”
According to the Society of Thoracic Surgery Adult Cardiac Surgery Database, isolated CABG for coronary artery disease (CAD) is the most commonly performed cardiac surgery procedure, with over 162,000 per year.1 The increased age of patients, in addition to risk factors for CAD (hypertension, diabetes, obesity and chronic kidney disease), increases the perioperative risk for acute kidney injury and subsequent fluid overload. Excess fluid overload in the perioperative phase of care has been associated with increased morbidity and mortality for CABG patients.2
“We are pleased with the results of this first-of-its-kind study highlighting the benefits of Aquadex therapy for high-risk CABG patients,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “The Aquadex System offers a significant opportunity to the medical community to improve clinical outcomes. In 2019, we made the decision to expand our strategic focus to include the use of Aquadex in critical care (cardiac surgery) and pediatric settings. Today, critical care represents approximately
In addition to cardiovascular surgery, Nuwellis continues to make significant progress in other key areas of patient need, including heart failure and pediatrics. The company recently announced the first patient enrolled in its REVERSE-HF clinical study, which is evaluating the clinical outcomes and economic value of its Aquadex® ultrafiltration therapy in comparison to intravenous (IV) diuretics for the treatment of fluid overload in patients with worsening heart failure. Nuwellis is also developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This device is being funded in part by a
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and predictable method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
1 Bowdish ME, D’Agostino RS, Thourani VH, Schwann TA, Krohn C, Desai N, Shahian DM, Fernandez FG, Badhwar V. STS Adult Cardiac Surgery Database: 2021 Update on Outcomes, Quality, and Research. Ann Thorac Surg 2021;111:1770-80.
2 Pal S. Primary Causes of End-Stage Renal Disease. US Pharm. 2016;41(8):6.
FAQ
What clinical data did Nuwellis release regarding the Aquadex system for CABG patients?
How does ultrafiltration with Aquadex benefit CABG patients?
What is the significance of the recent study published by Nuwellis in the Journal of Cardiac Surgery?
What percentage of Nuwellis' revenue comes from critical care settings?
What future research does Nuwellis plan following the positive results of the ultrafiltration study?
